Loading…
Loading…
can you give us some help on the proportion of sales from Skyrizi in IBD now or percentage of number of scripts getting IBD induction
did the strong performance include any notable onetime contributions, inventory build or pull forward effects
did you see any notable difference in trends in stocking or gross-to-net patterns across the portfolio ahead of the changes in Part D
Do you see increasing commercial competition from Leqvio in general? And going forward, there is going to be some late-stage data oral PCSK9 this year.
how you thinking about the weight loss for orfo in the ATTAIN obesity studies?
Could that be a reasonable comp for the obesity studies in '26, unlike what you flagged with ortho and diabetes?
does this One Big Beautiful Bill update effectively shift KEYTRUDA's IRA selection from 2028 to 2029
can you perhaps talk about your manufacturing footprint from China, Mexico and Canada